The Power & Industrial Construction division of Unibep has signed an agreement with Fresenius Kabi Polska for the implementation of an investment called “Construction of a laboratory building with internal and external installations in Kutno.” The agreement is worth PLN 12.6 million net. This is already the second investment the General Contractor will implement on behalf of Fresenius Kabi Polska.
“I am extremely proud and pleased with our victory in the tender for the construction of the laboratory facility. This shows that our company not only has excellent skills and experience but also the potential to undertake such important projects. This is already the second investment commissioned by the pharmaceutical industry in the history of Unibep,” said Przemysław Janiszewski, Member of the Board of Unibep and Director of Power & Industrial Construction.
The Agreement on behalf of Fresenius Kabi Polska was signed by Tomasz Halik, Member of the Board. Unibep, as the General Contractor, was represented by Przemysław Janiszewski.
About the investment
The building will consist of and administrative and laboratory part on the ground floor, and a technical part on the first floor. In the laboratory section, physicochemical and microbiological tests will be performed for the purpose of the quality control of products manufactured in the existing production plant.
Structure parameters:
- Height: 10.44 m
- Building footprint: 1,065.00 m2
- Usable area: 1,181.40 m2
- Volume: 8,088.15 m3
- Above-ground storeys: ground floor plus extension of the technical floor
Unibep will commence construction works later this year in December. And the completion of the investment is planned for December 2024.
It is worth adding that in 2019, for the same investor, Unibep completed the expansion of an existing production plant, that is, an infusion fluids factory in Kutno.
About the Investor
The Fresenius Group is a German healthcare company. It provides products and services for dialysis, hospitals, and inpatient and outpatient medical care. It also manages hospitals and provides engineering and services for medical centres and other healthcare facilities. The company is listed on the Frankfurt Stock Exchange. It employs over 300 thousand people worldwide.
The Group comprises operational companies Fresenius Kabi and Fresenius Helios as well as investment companies Fresenius Medical Care and Fresenius Vamed.
Fresenius Kabi is a global healthcare company specialising in the production of clinical nutrition, life-saving drugs, infusion and transfusion technology. Their products and services help in caring for critically and chronically ill patients.
